Join us in Vienna at the upcoming 𝗜𝗨𝗜𝗦 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 - 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗶𝗻 𝗜𝗻𝗳𝗹𝗮𝗺𝗺𝗮𝘁𝗶𝗼𝗻 & 𝗜𝗺𝗺𝘂𝗻𝗼𝗹𝗼𝗴𝘆, taking place 17 - 22 August! 𝗧𝘄𝗼 𝗼𝗳 𝗼𝘂𝗿 𝘁𝗮𝗹𝗲𝗻𝘁𝗲𝗱 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁𝘀 𝘄𝗶𝗹𝗹 𝗯𝗲 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗶𝗻𝗴 𝘁𝗵𝗲𝗶𝗿 𝗹𝗮𝘁𝗲𝘀𝘁 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵: • 𝗗𝗿. Ariane Walsh, Principal Scientist, will present her poster: “𝘜𝘯𝘤𝘰𝘷𝘦𝘳𝘪𝘯𝘨 𝘯𝘰𝘷𝘦𝘭 𝘵𝘢𝘳𝘨𝘦𝘵𝘴 𝘵𝘰 𝘣𝘰𝘰𝘴𝘵 𝘳𝘦𝘨𝘶𝘭𝘢𝘵𝘰𝘳𝘺 𝘛 𝘤𝘦𝘭𝘭 𝘱𝘩𝘦𝘯𝘰𝘵𝘺𝘱𝘦.” • 𝗗𝗿. Olha Novokhatska, Scientist, will present: “𝘔𝘶𝘭𝘵𝘪-𝘮𝘰𝘥𝘢𝘭 𝘪𝘯𝘵𝘦𝘳𝘳𝘰𝘨𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘢𝘶𝘵𝘰𝘪𝘮𝘮𝘶𝘯𝘦 𝘥𝘪𝘴𝘦𝘢𝘴𝘦 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘳𝘦𝘷𝘦𝘢𝘭𝘴 𝘩𝘪𝘨𝘩𝘭𝘺 𝘥𝘪𝘷𝘦𝘳𝘴𝘦 𝘣𝘪𝘰𝘮𝘢𝘳𝘬𝘦𝘳 𝘴𝘪𝘨𝘯𝘢𝘵𝘶𝘳𝘦𝘴.” Also attending will be 𝗗𝗿. Maximilian Naujock, who represents our global business development team to discuss potential business relationships related to Evotec’s preclinical assets, platform technologies, and RnD capabilities. We’re looking forward to connecting with you. See you in Vienna! 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗮𝗯𝗼𝘂𝘁 𝘁𝗵𝗲 𝗰𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗵𝗲𝗿𝗲- https://hubs.ly/Q03BTVcX0 #Evotec #IUIS2025 #Immunology #Inflammation #ScientificResearch #ConferenceParticipation #Biotech
Info
Evotec is a biotechnology company that is committed to advancing drug discovery and development. Through flexible business models, we collaborate with pharmaceutical companies, biotechs, foundations, and government agencies on a substantial scale. We believe that by working together, we can make a difference in the lives of patients. Our Pipeline Co-Creation model represents our adaptable, multi-modality, fully integrated end-to-end approach to drive collaborations and services across all phases of drug discovery and development – from discovery of novel targets to achieving Proof of Concept in the clinic and into commercial manufacturing. We aspire to contribute data-driven disease understanding and early disease relevance in humans to bring the probability of success up. We select the right modality, which is then propelled forward on our platforms by our passionate people striving for the fastest and most effective ways towards patient impact. This is enabled by convergence of human ingenuity with data and AI. We also offer specific solutions, products, and CRO/CDMO-like services, always in support of the Biopharma R&D innovator. Our more than 4,000 scientists work closely with numerous partners concurrently, delivering fully integrated research and development portfolios or individual projects with the highest quality standards and efficiency, coupled with great science, passion, engagement, and communication.
- Website
-
http://www.evotec.com
Externer Link zu Evotec
- Branche
- Biotechnologieforschung
- Größe
- 5.001–10.000 Beschäftigte
- Hauptsitz
- Hamburg
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 1993
- Spezialgebiete
- CNS, Oncology, Pain, Neurosciences, Inflammation, Metabolic disease, Infection, Respiratory diseases, Drug-Discovery, CMC, IND enabling und Drug Development
Orte
Beschäftigte von Evotec
Updates
-
𝗡𝗲𝘄 𝗼𝗻 𝘁𝗵𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗣𝗼𝗼𝗹, 𝗼𝘂𝗿 𝗼𝗻𝗹𝗶𝗻𝗲 𝗿𝗲𝘀𝗼𝘂𝗿𝗰𝗲 𝗵𝘂𝗯! Tuberculosis (TB) remains one of the deadliest infectious diseases worldwide — and drug resistance is on the rise. At Evotec, we’re tackling this global challenge head-on with a comprehensive, 𝗲𝗻𝗱-𝘁𝗼-𝗲𝗻𝗱 𝗧𝗕 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝘁𝗵𝗮𝘁 𝘀𝗽𝗮𝗻𝘀: • Target ID & validation • In vitro & in vivo efficacy models • Biomarker development • Global partnerships & access to clinical expertise 𝗢𝘂𝗿 𝗹𝗮𝘁𝗲𝘀𝘁 𝗯𝗹𝗼𝗴 𝗱𝗶𝘃𝗲𝘀 𝗶𝗻𝘁𝗼 𝗵𝗼𝘄 𝘄𝗲'𝗿𝗲 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝗽𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗕 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 - with the right science, the right infrastructure, and the right global collaborators. One platform. Many possibilities. A clear path from discovery to the clinic. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲- https://hubs.ly/Q03B5pF20 #TB #Tuberculosis
-
-
We’re excited to showcase our latest innovations in antibody discovery as we unveil how Evotec’s integrated Surface Plasmon Resonance (SPR) platform is transforming the biologics landscape. 𝗙𝗿𝗼𝗺 𝗼𝗳𝗳-𝗿𝗮𝘁𝗲 𝗿𝗮𝗻𝗸𝗶𝗻𝗴 𝘁𝗼 𝗲𝗽𝗶𝘁𝗼𝗽𝗲 𝗯𝗶𝗻𝗻𝗶𝗻𝗴 𝗮𝗻𝗱 𝗙𝗰 𝗿𝗲𝗰𝗲𝗽𝘁𝗼𝗿 𝗯𝗶𝗻𝗱𝗶𝗻𝗴, 𝗼𝘂𝗿 𝗮𝘂𝘁𝗼𝗺𝗮𝘁𝗲𝗱, 𝗵𝗶𝗴𝗵-𝘁𝗵𝗿𝗼𝘂𝗴𝗵𝗽𝘂𝘁 𝗦𝗣𝗥 𝘄𝗼𝗿𝗸𝗳𝗹𝗼𝘄𝘀 𝗲𝗻𝗮𝗯𝗹𝗲: • Screening of up to 1,800 Fabs/week with just 2 µL of supernatant • 48x48 epitope binning in a single run • Seamless integration from hit ID to clinical development Whether you're working with classical IgGs, bispecifics, ADCs, or VHHs, our SPR platform supports robust, scalable, and cost-effective antibody characterization. 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗼𝘀𝘁𝗲𝗿- https://hubs.ly/Q03B5p0X0 #BiologicsDiscovery #SPR #AntibodyDiscovery
-
-
We are excited that Carleen Kluger, Group leader in Clinical Proteomics, is featured in The Medicine Maker's 𝗹𝗮𝘁𝗲𝘀𝘁 𝗽𝗶𝗲𝗰𝗲 𝗼𝗻 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲! In Chapter 9: Personalized, Precise Treatments, Carleen shares powerful insights on how data-driven, individualized approaches are reshaping drug development and patient care. A must-read for anyone in pharma, biotech, or healthcare innovation. 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝗻𝗼𝘄- https://hubs.ly/Q03Bhnsj0 #PrecisionMedicine #PersonalizedHealthcare #PharmaInnovation
-
-
𝗪𝗮𝘁𝗰𝗵 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗘𝘅𝗽𝗲𝗿𝘁𝘀 𝗧𝗮𝗹𝗸- https://hubs.ly/Q03Bhnv60 𝗘𝘅𝗽𝗲𝗿𝘁𝘀 𝗧𝗮𝗹𝗸: 𝗛𝗶𝗴𝗵-𝗦𝗲𝗻𝘀𝗶𝘁𝗶𝘃𝗶𝘁𝘆 𝗕𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝘀 𝗶𝗻 𝗡𝗲𝘂𝗿𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲 Join two of our leading scientists in this expert roundtable as they discuss how high-sensitivity biomarkers are reshaping neuroscience research and therapeutic strategies. #PrecisionMedicine #Biomarkers #Neuroscience #Evotec
-
Our fully integrated CRISPR-based platform enables robust target identification and validation in primary human immune cells - advancing drug discovery in autoimmune, inflammatory, and immuno-oncology areas. 𝗞𝗲𝘆 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗼𝗳 𝗿𝗲𝗰𝗲𝗻𝘁 𝗽𝗼𝘀𝘁𝗲𝗿 𝗶𝗻𝗰𝗹𝘂𝗱𝗲: • Druggable genome-wide #CRISPR screen in primary human regulatory T cells • Identification of 774 FoxP3 regulators with potential applications in I&I and I/O • Functional validation via cytokine release, metabolic assays, and co-culture assays • Platform offers seamless integration with Evotec’s phenotypic screening and bioinformatics platforms • Additional validation options in various primary immune cells T-cell subsets, B cells, NK cells, monocytes, and macrophages 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗼𝘀𝘁𝗲𝗿- https://hubs.ly/Q03B5nT70 #Immunology #DrugDiscovery #TargetValidation #ImmunoOncology #AutoimmuneResearch
-
-
𝗔𝗻𝗮𝗹𝘆𝘁𝗶𝗰𝗮𝗹 𝗦𝘁𝘂𝗱𝗶𝗲𝘀 𝗮𝘁 𝗘𝘃𝗼𝘁𝗲𝗰: 𝗘𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲 𝗠𝗲𝗲𝘁𝘀 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 At Evotec, we are transforming analytical services through full digitalization. 𝗢𝘂𝗿 𝗽𝗿𝗼𝗽𝗿𝗶𝗲𝘁𝗮𝗿𝘆 𝗔𝗗𝗙𝗜 - 𝗔𝗻𝗮𝗹𝘆𝘁𝗶𝗰𝗮𝗹 𝗗𝗮𝘁𝗮 𝗙𝗹𝗼𝘄 𝗜𝗻𝘁𝗲𝗿𝗳𝗮𝗰𝗲 - developed with LabWare, is already live with a major pharma partner and was recently showcased at the 2025 LabWare European Customer Education Conference: https://hubs.ly/Q03B7YHf0 Why does this matter for stability and other analytical development studies? ADFI enables: • Automated, secure data transfer from our LIMS directly to your systems • Structured outputs in JSON, XML, or FHIR formats, ready for regulatory submission • Real-time access to protocols, reports, specifications, and test results • PQ/CMC-ready data flows, aligned with upcoming FDA and EMA requirements This future-ready solution ensures 𝗱𝗮𝘁𝗮 𝗶𝗻𝘁𝗲𝗴𝗿𝗶𝘁𝘆, 𝘁𝗿𝗮𝗰𝗲𝗮𝗯𝗶𝗹𝗶𝘁𝘆, 𝗮𝗻𝗱 𝘀𝗽𝗲𝗲𝗱 𝗳𝗿𝗼𝗺 𝗱𝗮𝘆 𝗼𝗻𝗲, especially for 𝗹𝗮𝘁𝗲-𝗽𝗵𝗮𝘀𝗲 𝗼𝗿 𝗰𝗼𝗺𝗽𝗹𝗲𝘅 𝘀𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗽𝗿𝗼𝗴𝗿𝗮𝗺𝘀. Learn more or speak with an expert: https://hubs.ly/Q03B7Wkn0 Download the factsheet here- https://hubs.ly/Q03BgTfy0 #StabilityStudies #DigitalLIMS #ADFI #RegulatoryScience #DrugDevelopment
-
At Evotec, we believe #RNA is more than just a messenger - it's a powerful gateway to next-generation therapeutics. From 𝗱𝗲𝗰𝗼𝗱𝗶𝗻𝗴 𝗥𝗡𝗔’𝘀 𝗰𝗼𝗺𝗽𝗹𝗲𝘅 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲𝘀 to designing small molecules that target disease-driving RNAs, our platforms are reshaping the future of medicine. • 𝗥𝗡𝗔-𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝘀𝗺𝗮𝗹𝗹 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗲𝘀: Unlocking new druggable space beyond proteins • 𝗺𝗥𝗡𝗔 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀: Delivering precision treatments for cancer, infectious, and genetic diseases • 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝘀𝗲𝗾𝘂𝗲𝗻𝗰𝗶𝗻𝗴 & 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲 𝗲𝗹𝘂𝗰𝗶𝗱𝗮𝘁𝗶𝗼𝗻: Driving discovery with next-generation technologies • 𝗧𝗿𝗮𝗻𝘀𝗰𝗿𝗶𝗽𝘁𝗼𝗺𝗶𝗰𝘀s: Identifying early markers of drug-induced toxicity On #WorldRNADay, we’re proud to be at the forefront of RNA biology - turning scientific insight into real-world impact. Learn more: https://hubs.ly/Q03zhQg50 #DrugDiscovery #mRNA #RNAtherapeutics #PrecisionMedicine #WorldRNADay
-
-
From tears to extracellular vesicles, we're 𝗽𝘂𝘀𝗵𝗶𝗻𝗴 𝘁𝗵𝗲 𝗯𝗼𝘂𝗻𝗱𝗮𝗿𝗶𝗲𝘀 𝗼𝗳 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 using ultra-sensitive platforms like SMCxPRO, Quanterix, MSD, and NULISA. 𝗧𝗵𝗲𝘀𝗲 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀 𝗮𝗿𝗲 𝗵𝗲𝗹𝗽𝗶𝗻𝗴 𝘂𝘀 𝗱𝗲𝘁𝗲𝗰𝘁 𝗱𝗶𝘀𝗲𝗮𝘀𝗲-𝗿𝗲𝗹𝗲𝘃𝗮𝗻𝘁 𝗽𝗿𝗼𝘁𝗲𝗶𝗻𝘀 in novel, non-invasive matrices - opening new doors for early diagnosis, patient stratification, and monitoring in complex diseases like Huntington’s and SCA3. Dive into the full poster here: https://hubs.ly/Q03z35-x0 #Biomarkers #Neurodegeneration #Immunoassays
-
-
𝗘𝘃𝗼𝘁𝗲𝗰 𝗮𝗻𝗱 Cyprotex 𝘄𝗶𝗹𝗹 𝗮𝘁𝘁𝗲𝗻𝗱 𝘁𝗵𝗲 𝗗𝗠𝗗𝗚 𝟱𝟭𝘀𝘁 𝗔𝗻𝗻𝗶𝘃𝗲𝗿𝘀𝗮𝗿𝘆 𝗢𝗽𝗲𝗻 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝘁𝗵𝗶𝘀 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿. Dermot McGinnity, our EVP Head of Global Discovery DMPK, will be amongst the speakers in the 2025 DMDG Debate session, which will address the following motion: "This house believes that social media has more potential to positively impact drug discovery and development than peer reviewed articles". • 𝗖𝗮𝗺𝗯𝗿𝗶𝗱𝗴𝗲, 𝗨𝗞 • 𝗦𝗲𝘀𝘀𝗶𝗼𝗻 𝟵: 𝗧𝗵𝗲 𝗗𝗠𝗗𝗚 𝗗𝗲𝗯𝗮𝘁𝗲 • 𝗪𝗲𝗱𝗻𝗲𝘀𝗱𝗮𝘆 𝟯𝗿𝗱 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿, 𝟭𝟳:𝟯𝟬 𝗕𝗦𝗧 Arrange meetings with our colleagues, Steve Madden, SVP, Head, Global Operations Cyprotex and Rachel Upcott Gill, Principal Scientist, Drug Metabolism https://hubs.ly/Q03zfFy60
-